SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

Home・Akciju saraksts・Pharma Mar SA

P
Pharma Mar SA

Atvērts

98.85 5.67

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

92.15

Max

99.5

Galvenie mērījumi
By Trading Economics
Ienākumi	-58M 1.6M
Pārdošana	-48M 43M
P/E Sektora vidējais	21.191 49.888
EPS	0.088
Peļņas marža	3.725
Darbinieki	505
EBITDA	-40M 2.7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+27.25% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	40M 1.7B
Iepriekšējā atvēršanas cena	93.18
Iepriekšējā slēgšanas cena	98.85

Pharma Mar SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. jūn. 21:51 UTC

Galvenie tirgus virzītāji

Merlin Shares Rally After Defense Department's Design Review Wraps

2026. g. 4. jūn. 23:46 UTC

Tirgus saruna

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026. g. 4. jūn. 23:44 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 4. jūn. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026. g. 4. jūn. 23:41 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia to Enter Trading Halt

2026. g. 4. jūn. 23:34 UTC

Tirgus saruna

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 4. jūn. 23:08 UTC

Tirgus saruna

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026. g. 4. jūn. 22:41 UTC

Tirgus saruna

Australia Shares Set to Rise at the Open -- Market Talk

2026. g. 4. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 20:44 UTC

Iegādes, apvienošanās, pārņemšana

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026. g. 4. jūn. 20:16 UTC

Tirgus saruna

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026. g. 4. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026. g. 4. jūn. 19:46 UTC

Tirgus saruna

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026. g. 4. jūn. 19:38 UTC

Tirgus saruna

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026. g. 4. jūn. 19:30 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026. g. 4. jūn. 18:47 UTC

Iegādes, apvienošanās, pārņemšana

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026. g. 4. jūn. 18:38 UTC

Peļņas

Money Quote: Tech Weakness in Context -- WSJ

2026. g. 4. jūn. 18:24 UTC

Peļņas

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 17:09 UTC

Tirgus saruna

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026. g. 4. jūn. 16:58 UTC

Peļņas

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 16:46 UTC

Tirgus saruna

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026. g. 4. jūn. 16:38 UTC

Peļņas

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 4. jūn. 16:13 UTC

Tirgus saruna

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026. g. 4. jūn. 16:11 UTC

Tirgus saruna

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026. g. 4. jūn. 15:56 UTC

Tirgus saruna

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pharma Mar SA Prognoze

Cenas mērķis

By TipRanks

27.25% augšup

Prognoze 12 mēnešiem

Vidējais 120.502 EUR 27.25%

Augstākais 121 EUR

Zemākais 120 EUR

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pharma Mar SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pharma Mar SA — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.